Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
Liposits, Gabor; Ryg, Jesper; Skuladottir, Halla; Winther, Stine B.; Möller, Sören; Hofsli, Eva; Shah, Carl Henrik; Poulsen, Laurids Østergaard; Berglund, Åke; Qvortrup, Camilla; Osterlund, Pia; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per (2022)
Liposits, Gabor
Ryg, Jesper
Skuladottir, Halla
Winther, Stine B.
Möller, Sören
Hofsli, Eva
Shah, Carl Henrik
Poulsen, Laurids Østergaard
Berglund, Åke
Qvortrup, Camilla
Osterlund, Pia
Glimelius, Bengt
Sorbye, Halfdan
Pfeiffer, Per
2022
JOURNAL OF GERIATRIC ONCOLOGY
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202302102278
https://urn.fi/URN:NBN:fi:tuni-202302102278
Kuvaus
Peer reviewed
Tiivistelmä
<p>Introduction: Appropriate patient selection based on functional status is crucial when considering older adults for palliative chemotherapy. This pre-planned analysis of the randomized NORDIC9-study explored the prognostic value of four functional status measures regarding progression-free survival (PFS) and overall survival (OS) in vulnerable older patients with metastatic colorectal cancer (mCRC) receiving first-line palliative chemotherapy. Materials and methods: Patients ≥70 years of age with mCRC not candidates for standard full-dose combination chemotherapy were randomized to receive full-dose S1 or reduced-dose S1 + oxaliplatin. At baseline, functional status was assessed using ECOG performance status (ECOG PS), frailty phenotype, Geriatric 8 (G8), and Vulnerable Elderly Survey-13 (VES-13). Multivariable regression models were applied and C-statistics were estimated. Results: In total, 160 patients with a median age of 78 years (IQR: 76–81) were included. While in univariate analyses, ECOG PS, frailty phenotype, and VES-13 were statistically significantly associated with differences in OS between subgroups, G8 was not (HR = 1.55, 95%CI: 0.99–2.41, p = 0.050). In multivariable analyses adjusted for age, sex, body mass index, and treatment allocation, we found significant differences between subgroups for all applied tools and with C-statistics in the moderate range for ECOG PS and VES-13. Concerning PFS, statistically significant differences were observed between subgroups of ECOG PS, G8, and VES-13 both in uni- and multivariable analyses, but not for frailty phenotype. Discussion: In this Nordic cohort of vulnerable older patients with mCRC, baseline ECOG PS, frailty phenotype, G8, and VES-13 showed prognostic value regarding overall survival, and moderate predictive value of models based on ECOG PS and VES-13 was demonstrated.</p>
Kokoelmat
- TUNICRIS-julkaisut [20039]